AI Blood Test for Dogs: A New Era in Proactive Pet Healthcare Begins

OXFORD, United Kingdom – July 01, 2026 – A single blood sample, taken during a routine check-up, could soon give veterinarians an unprecedented look into a dog's health, flagging the chemical signatures of cancer or cardiovascular disease long before any physical symptoms appear. This isn't a futuristic concept; it's the validated reality presented by LatusPet, a University of Oxford biotech startup that has combined advanced blood analysis with machine learning to create a diagnostic tool poised to revolutionize veterinary medicine.

In a peer-reviewed study published today in Frontiers in Veterinary Science, researchers detailed the success of the company's proprietary SINO platform. The technology demonstrated over 90% accuracy in detecting major diseases from a small serum sample, a breakthrough that promises to shift the entire paradigm of pet care from reactive treatment to proactive, life-extending wellness.

The Science Behind the Signature

At the heart of LatusPet's innovation is the fusion of two powerful technologies: Nuclear Magnetic Resonance (NMR) metabolomics and artificial intelligence. Every disease process, from a developing tumor to a failing heart, creates subtle shifts in an organism's metabolism. These changes leave a distinct trail of molecular byproducts, or metabolites, in the bloodstream. NMR spectroscopy provides a highly detailed and reproducible snapshot of these metabolites, creating a complex chemical profile.

"Disease leaves a chemical signature in the blood, and we have learned to read that signature in dogs," explained Prof. Daniel C. Anthony, Chief Scientific Officer at LatusPet and a professor at the University of Oxford. "From a single sample we can assess several conditions at once, a depth of insight that has not been available in veterinary medicine before."

This is where machine learning comes in. The SINO platform's AI has been trained on thousands of these complex profiles to recognize the specific patterns associated with different diseases. The study, led by leading European veterinary oncologist Prof. Riccardo Finotello, was notable for its rigorous methodology. Instead of a simple comparison of 'sick' versus 'healthy' animals, the platform was challenged to distinguish a specific disease from a realistic mix of other conditions and healthy dogs simultaneously. This more demanding test mirrors the complexity of a real-world clinical setting and validates the platform's robustness.

A Paradigm Shift in Pet Care

For decades, veterinary medicine, much like human medicine, has largely operated on a reactive basis. A pet is brought to the clinic when it displays signs of illness—lethargy, loss of appetite, a noticeable limp or lump. By this stage, a disease may already be advanced, making treatment more difficult, costly, and less likely to succeed. LatusPet's technology offers a powerful alternative.

"This is the kind of science that changes a profession," said Dr. Simone Scoccianti, LatusPet's Chief Veterinary Officer. "One blood draw at a routine check-up could flag risk before any clinical signs appear: the shift from reactive to proactive care."

This shift addresses a significant gap in the companion animal market. While diagnostic innovation for humans has surged ahead, the tools available for our pets have often lagged. Current screening for conditions like cancer or heart disease can require multiple, often invasive and expensive, specialized tests. The SINO platform's ability to screen for multiple conditions—including cancer, cardiovascular, kidney, and gastrointestinal diseases—from a single, minimally invasive 0.25 mL serum sample represents a monumental leap in efficiency and accessibility.

For pet owners, this translates into actionable knowledge and peace of mind. The ability to catch a disease in its infancy empowers them and their veterinarians to intervene earlier, potentially leading to better outcomes and, most importantly, more quality time with their companions.

From Lab Bench to Veterinary Clinic

LatusPet's journey exemplifies the power of translating world-class academic research into a commercially viable tool with real-world impact. The company's origin story is a collaboration between Dr. Bobo Nazarov, a former venture capitalist inspired by personal experience with pet illness, and Prof. Anthony, whose work at Oxford focuses on biomarker discovery. Together, they adapted cutting-edge multi-omics approaches, previously focused on human health, for the specific needs of companion animals.

The company’s mission is not just scientific validation, but widespread adoption. "We have proven that the science works," stated Dr. Nazarov, Founder of LatusPet. "Our mission now is to put this technology into the hands of every vet, so no treatable disease goes undetected for want of the right test."

The operational model is designed for simplicity. Veterinarians perform a standard blood draw and send the serum sample to LatusPet for analysis. No special equipment or training is required at the clinic level. The clinic then receives a detailed report to discuss with the pet owner, enabling them to formulate a proactive health plan. By removing technical and financial barriers, the company hopes to rapidly integrate this powerful screening tool into the annual wellness exam for dogs.

The Road Ahead for Animal Health

The publication of this foundational study is just the beginning. LatusPet is already expanding its research to include larger cohorts of animals and has a clear roadmap for the future. The company plans to add new disease screenings to its panel each year and is actively working to extend the SINO platform's capabilities to other species, with cats being a logical next step.

Furthermore, the potential applications extend beyond initial detection. As Prof. Finotello noted, the technology holds immense promise for the non-invasive monitoring of treatment. Veterinarians could use subsequent SINO tests to track a patient's response to therapy or to monitor for remission, providing a quantitative measure of success that goes beyond subjective clinical signs.

As LatusPet seeks more veterinary partners to help build this new ecosystem of proactive care, it's clear that a significant milestone has been reached. The ability to read the subtle, predictive language of the bloodstream marks a turning point not just for the veterinary diagnostics industry, but for the fundamental relationship between humans and the animals they love. For millions of pet owners, this shift from anxious waiting to proactive knowledge represents not just better medicine, but a new definition of care.